Nearly 450 Innovative Medicines in Development for Neurological Disorders

barbara.lempert

WASHINGTON, D.C. (July 31, 2013) – America’s biopharmaceutical research companies are developing 444 new to prevent and treat , according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).
There are more than 600 neurological disorders that strike millions of Americans each year. These disorders inflict great pain and suffering on millions of patients and their families, and cost the U.S. economy billions of dollars annually. They range from well-known disorders such as epilepsy, multiple sclerosis and Parkinson’s disease, to more obscure conditions such as Duchenne muscular dystrophy and Friedreich’s ataxia.
“Despite the incredible complexity of neurological disorders, biopharmaceutical scientists have delivered significant advances for patients in recent years, including new medicines for multiple sclerosis and Huntington’s disease,” said PhRMA President and CEO John J. Castellani. “The 450 medicines in the pipeline have the potential to bring us ever closer to our shared goal of improving the health and extending the lives, of patients facing these debilitating disorders.”
These potential medicines – all in human clinical trials or under review by the Food and Drug Administration (FDA) – are diverse in scope. They include:
•    82 medicines for Alzheimer’s disease, which afflicts more than 5 million Americans
•    82 for pain – 100 million U.S. adults experience chronic pain
•    62 for brain tumors – nearly 70,000 Americans are diagnosed each year with a primary brain tumor
•    38 for multiple sclerosis, which afflicts an estimated 500,000 Americans
•    25 for headache, including migraine, a condition that affects more than 37 million Americans
•    28 for epilepsy and seizures, which impacts more than 3 million Americans
•    27 for Parkinson’s disease, which affects as many as 1million Americans…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS